Evidence map›Paper›PMID 31372720›Full record

ArticleRheumatology international2019

Sarcopenia in systemic sclerosis: the impact of nutritional, clinical, and laboratory features.

Claudio Corallo, Antonella Fioravanti, Sara Tenti, Gianluca Pecetti, Ranuccio Nuti, Nicola Giordano

Abstract read
PubMed Publisher
In one paragraph

Article in Rheumatology international, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 4 pooled it
4.6field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 4 syntheses or guidelines pooled it, 52 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Claudio CoralloScleroderma Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy. corallo.claudio@gmail.com.ORCID http://orcid.org/0000-0003-2826-3745
Antonella FioravantiRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-7325-5579
Sara TentiRheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0002-6011-7134
Gianluca PecettiMedical and Scientific Direction, Actelion Pharmaceuticals Italia, Imola, Italy.
Ranuccio NutiScleroderma Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0003-2380-7432
Nicola GiordanoScleroderma Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.ORCID http://orcid.org/0000-0001-5423-437X
University of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We evaluated the presence of sarcopenia in a population of systemic sclerosis (SSc) patients, with respect to nutritional, clinical, and laboratory features. A total of 62 patients who met the ACR/EULAR 2013 classification criteria were enrolled. Sarcopenia was defined according to the Relative Skeletal Mass Index (RSMI) and hand grip strength (HGS). Body composition was assessed with the calculation of the Body Mass Index (BMI), lean body mass (LBM) and fat mass (FM). Malnutrition was evaluated according to the ESPEN criteria. Clinical evaluation included nailfold capillaroscopy and skin evaluation by modified Rodnan Skin Score (mRSS), pulmonary function tests (PFT) with diffusing capacity for carbon monoxide adjusted for hemoglobin (DLCO), high-resolution computed tomography (HR-CT) of the lungs, echocardiography and high-resolution manometry (HRM) for esophageal involvement. Laboratory evaluation included erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), hemoglobin, creatinine, creatine kinase (CK), transaminases, lipid profile, glycemia, albumin, and vitamin-D. Antinuclear antibodies (ANA) and extractable nuclear antigens (ENA) were also assessed. Considering RSMI, the prevalence of sarcopenia is 42%. In this case, age, malnutrition, disease duration, mRSS, capillaroscopy score, esophageal involvement, ESR, and ANA titer are higher in the sarcopenic group, while DLCO and LBM are lower. Considering HGS, the prevalence of sarcopenia is 55%. Age, disease duration, malnutrition, FM, mRSS, capillaroscopy score, esophageal involvement, ESR, and ENA positivity are higher in the sarcopenic group, while DLCO is lower. By using both RSMI and HGS to assess sarcopenia in SSc, the results of this study demonstrated that this condition correlates with different nutritional, clinical, and biochemical parameters associated with the worsening of the disease.

Indexed as

Body CompositionHand StrengthNutritional StatusAdiposityAdultAgedDisease ProgressionFemaleHumansItalyMaleMalnutritionMiddle AgedPredictive Value of TestsPrevalencePrognosisHand Grip Strength (HGS)MalnutritionRelative Skeletal Mass Index (RSMI)SarcopeniaSystemic sclerosis

Identifiers

PMID31372720
OpenAlexW2965087052

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.